A tissue-engineered stent for cell-based vascular gene transfer.

Abstract:

:Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronectin provided an excellent platform for adherent porcine smooth muscle cells (SMC). Autologous porcine SMC were stably transduced with a plasmid encoding green fluorescence protein (GFP), seeded at high density in the mesh-stent, and deployed in the porcine coronary artery. Stable in vivo GFP expression within the mesh-stent (5.2 x 10(5) GFP-positive cells/cm(2) mesh) was demonstrated 1 month after implantation in the porcine coronary artery by fluorescence microscopy and flow cytometry. No significant change in GFP positive cell number within the stent occurred over a 1-month period in vivo when compared to preinsertion. Angiographic and histologic analysis revealed mild neointimal proliferation and no inflammatory infiltrate in the stented segment. This study has implications for treatment of cardiovascular and other diseases where long-term cell-based delivery of transgene is a desirable therapeutic option.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Panetta CJ,Miyauchi K,Berry D,Simari RD,Holmes DR,Schwartz RS,Caplice NM

doi

10.1089/10430340252792567

keywords:

subject

Has Abstract

pub_date

2002-02-10 00:00:00

pages

433-41

issue

3

eissn

1043-0342

issn

1557-7422

journal_volume

13

pub_type

杂志文章
  • Inhibitory effect of nuclear factor-κB decoy oligodeoxynucleotide on liver fibrosis through regulation of the epithelial-mesenchymal transition.

    abstract::The epithelial-mesenchymal transition (EMT) has been recognized to occur during embryonic development, fibrosis, and tumor metastasis. Nuclear factor (NF)-κB plays a central role in mediating the inflammation and wound-healing responses during liver fibrogenesis. However, the involvement of NF-κB during EMT in liver c...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2013.106

    authors: Kim KH,Lee WR,Kang YN,Chang YC,Park KK

    更新日期:2014-08-01 00:00:00

  • Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy.

    abstract::The gene therapy strategy using the hsvl-thymidine kinase gene (TK) and ganciclovir (GCV) injections that has been used for treating human glioblastomas has not been as effective as expected after the first animal experiments. A better understanding of the different steps involved in this treatment, like gene transfer...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.16-1945

    authors: Sturtz FG,Waddell K,Shulok J,Chen X,Caruso M,Sanson M,Snodgrass HR,Platika D

    更新日期:1997-11-01 00:00:00

  • In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors.

    abstract::Tumor angiogenesis is a rate-limiting factor for tumor growth, and the endothelial cells of tumor vessels display specific features that can be exploited for the selective delivery of cancer therapeutics. To specifically target exogenous genes to angiogenic tumor vessels, we generated a panel of vesicular stomatitis v...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403322168028

    authors: De Palma M,Venneri MA,Naldini L

    更新日期:2003-08-10 00:00:00

  • Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice.

    abstract::Adenoviral vectors used in gene therapy are predominantly derived from adenovirus serotype 5 (Ad5), which infects a broad range of cells. Ad5 cell entry involves interactions with the coxsackie-adenovirus receptor (CAR) and integrins. To assess these receptors in vivo, we mutated amino acid residues in fiber and pento...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403765255165

    authors: Smith TA,Idamakanti N,Rollence ML,Marshall-Neff J,Kim J,Mulgrew K,Nemerow GR,Kaleko M,Stevenson SC

    更新日期:2003-05-20 00:00:00

  • Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.

    abstract::The potential of short interfering RNA (siRNA) to be developed for therapeutic use against cancer depends on the availability of an efficient tumor-specific delivery vehicle. We have previously shown that a nanoscale nonviral liposome-based complex that includes an anti-transferrin receptor single-chain antibody fragm...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.117

    authors: Pirollo KF,Zon G,Rait A,Zhou Q,Yu W,Hogrefe R,Chang EH

    更新日期:2006-01-01 00:00:00

  • Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients.

    abstract::Immunologically sensitized recipients present one of the most critical problems in clinical organ transplantation today, since preformed antibodies rapidly destroy donor tissue expressing specific MHC class I antigens (Ag). Therefore, sensitized patients are either unable to receive a compatible organ, or experience a...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050015923

    authors: Geissler EK,Graeb C,Tange S,Guba M,Jauch KW,Scherer MN

    更新日期:2000-02-10 00:00:00

  • A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.

    abstract::Ornithine transcarbamylase deficiency (OTCD) is an inborn error of urea synthesis that has been considered as a model for liver-directed gene therapy. Current treatment has failed to avert a high mortality or morbidity from hyperammonemic coma. Restoration of enzyme activity in the liver should suffice to normalize me...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340152712719

    authors: Raper SE,Yudkoff M,Chirmule N,Gao GP,Nunes F,Haskal ZJ,Furth EE,Propert KJ,Robinson MB,Magosin S,Simoes H,Speicher L,Hughes J,Tazelaar J,Wivel NA,Wilson JM,Batshaw ML

    更新日期:2002-01-01 00:00:00

  • Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

    abstract::Adenovirus type 5 (Ad5) is a commonly used vector for gene therapy, but its efficacy is limited by high seroprevalence and off-target hepatic and splenic sequestration. In order to circumvent these limitations, the use of vectors derived from rare species adenoviruses is appealing. The opportunity to retarget rare spe...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2014.016

    authors: Coughlan L,Uusi-Kerttula H,Ma J,Degg BP,Parker AL,Baker AH

    更新日期:2014-04-01 00:00:00

  • DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4+ T cells.

    abstract::La Crosse virus (LACV)-mediated encephalitis is the most frequently reported arboviral disease in the United States, but to date no vaccine against this virus is available. We have established a new animal model, genetically targeted mice lacking a functional interferon type I receptor (IFNAR-1). These mice show an ag...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950017653

    authors: Schuh T,Schultz J,Moelling K,Pavlovic J

    更新日期:1999-07-01 00:00:00

  • Regulatory and ethical issues for phase I in utero gene transfer studies.

    abstract::Clinical gene transfer research has involved adult and child subjects, and it is expected that gene transfer in fetal subjects will occur in the future. Some genetic diseases have serious adverse effects on the fetus before birth, and there is hope that prenatal gene therapy could prevent such disease progression. Res...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2011.062

    authors: Strong C

    更新日期:2011-11-01 00:00:00

  • Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use.

    abstract::Vectors derived from the human parvovirus AAV-2 (adeno-associated virus type 2) are among the most promising gene delivery vehicles currently being developed. These vectors are not only capable of transducing a large variety of human cell types in vitro and in vivo, but in immunocompetent animal models can establish l...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/10430349950016799

    authors: Grimm D,Kleinschmidt JA

    更新日期:1999-10-10 00:00:00

  • E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.

    abstract::Gene-modified replication-competent adenoviruses (Ads) are emerging as a promising new modality for the treatment of cancer. We have previously shown that E1B 19kDa and E1B 55kDa gene-deleted Ad (Ad-DeltaE1B19/55) exhibits improved tumor-specific replication and cell lysis, leading to an enhanced antitumor effect. In ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.167

    authors: Kim J,Kim JH,Choi KJ,Kim PH,Yun CO

    更新日期:2007-09-01 00:00:00

  • Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells.

    abstract::Adeno-associated viral vectors are showing great promise as gene therapy vectors for a wide range of retinal disorders. To date, evaluation of therapeutic approaches has depended almost exclusively on the use of animal models. With recent advances in human stem cell technology, stem cell-derived retina now offers the ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2018.027

    authors: Gonzalez-Cordero A,Goh D,Kruczek K,Naeem A,Fernando M,Kleine Holthaus SM,Takaaki M,Blackford SJI,Kloc M,Agundez L,Sampson RD,Borooah S,Ovando-Roche P,Mehat MS,West EL,Smith AJ,Pearson RA,Ali RR

    更新日期:2018-10-01 00:00:00

  • Maternal Therapy with Ad.VEGF-A165 Increases Fetal Weight at Term in a Guinea-Pig Model of Fetal Growth Restriction.

    abstract::In a model of growth-restricted sheep pregnancy, it was previously demonstrated that transient uterine artery VEGF overexpression can improve fetal growth. This approach was tested in guinea-pig pregnancies, where placental physiology is more similar to humans. Fetal growth restriction (FGR) was attained through peri-...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2016.046

    authors: Swanson AM,Rossi CA,Ofir K,Mehta V,Boyd M,Barker H,Ledwozyw A,Vaughan O,Martin J,Zachary I,Sebire N,Peebles DM,David AL

    更新日期:2016-12-01 00:00:00

  • Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.

    abstract::Silencing of Wnt antagonists with aberrant activation of Wnt signaling is a common phenomenon in various human cancers. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist of Wnt signaling and acts through direct binding to Wnt in the extracellular space. In this study, we tried to illuminate the impact of WIF-1 ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.005

    authors: Lin YC,You L,Xu Z,He B,Yang CT,Chen JK,Mikami I,Clément G,Shi Y,Kuchenbecker K,Okamoto J,Kashani-Sabet M,Jablons DM

    更新日期:2007-04-01 00:00:00

  • Upregulation of Bag-1 by ex vivo gene transfer protects rat livers from ischemia/reperfusion injury.

    abstract::Bag-1 exerts powerful antiapoptotic effects by binding and stabilizing Bcl-2 and interacting with the tumor necrosis factor receptor type I-induced death signal. We examined the effects of overexpression of Bag-1 by ex vivo adenoviral gene transfer on cold (4 degrees C for 24 hr) ischemia/reperfusion (I/R) injury of r...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340260185120

    authors: Sawitzki B,Amersi F,Ritter T,Fisser M,Shen XD,Ke B,Busuttil R,Volk HD,Kupiec-Weglinski JW

    更新日期:2002-08-10 00:00:00

  • Transient transfection methods for clinical adeno-associated viral vector production.

    abstract::Recombinant adeno-associated virus (AAV)-based vectors expressing therapeutic gene products have shown great potential for human gene therapy. One major challenge for translation of promising research to clinical development is the manufacture of sufficient quantities of AAV vectors that meet stringent standards for p...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2009.064

    authors: Wright JF

    更新日期:2009-07-01 00:00:00

  • Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope.

    abstract::Gene-modified lymphocytes have a potential role in the therapy of cancer, infectious diseases, and genetic disorders of the immune system. Current gene therapy protocols involving gene transfer into lymphocytes utilize retroviruses with amphotropic envelope proteins. However, transduction efficiencies in lymphocytes u...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.12-1415

    authors: Lam JS,Reeves ME,Cowherd R,Rosenberg SA,Hwu P

    更新日期:1996-08-01 00:00:00

  • Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer.

    abstract::Efficient DNA electrotransfer can be achieved with combinations of short high-voltage (HV) and long low voltage (LV) pulses that cover two effects of the pulses, namely, target cell electropermeabilization and DNA electrophoresis within the tissue. Because HV and LV can be delivered with a lag up to 3000 sec between t...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2005.16.1194

    authors: Satkauskas S,André F,Bureau MF,Scherman D,Miklavcic D,Mir LM

    更新日期:2005-10-01 00:00:00

  • Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.

    abstract::Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans (GAGs). We demonstrated that biochemical alterations in the brains of MPS II mice are not corrected by bone marrow transplantat...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2014.158

    authors: Wakabayashi T,Shimada Y,Akiyama K,Higuchi T,Fukuda T,Kobayashi H,Eto Y,Ida H,Ohashi T

    更新日期:2015-06-01 00:00:00

  • Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.

    abstract::The management of disorders of the nervous system remains a medical challenge. The key goals are to understand disease mechanisms, to validate therapeutic targets, and to develop new therapeutic strategies. Viral vector-mediated gene transfer can meet these goals and vectors based on lentiviruses have particularly use...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2006.17.1

    authors: Wong LF,Goodhead L,Prat C,Mitrophanous KA,Kingsman SM,Mazarakis ND

    更新日期:2006-01-01 00:00:00

  • Heat-directed tumor cell fusion.

    abstract::In previous studies we demonstrated that a modified human HSP70b promoter (HSE.70b) directs high levels of gene expression to tumor cells after mild hyperthermia treatment in the range of 41.5-44 degrees C. This transcriptional targeting system exhibits low basal activity at 37 degrees C, is highly induced (950-fold) ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403321467216

    authors: Brade AM,Szmitko P,Ngo D,Liu FF,Klamut HJ

    更新日期:2003-03-20 00:00:00

  • The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.

    abstract::Trans-dominant mutants of human immunodeficiency virus type 1 (HIV-1) Tat and Rev are attractive candidates for use in gene therapy in the treatment of HIV-1 infections because both are essential for viral replication. Retroviral vectors were constructed to allow either Tat-inducible or Tat- and Rev-inducible expressi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1993.4.5-625

    authors: Liem SE,Ramezani A,Li X,Joshi S

    更新日期:1993-10-01 00:00:00

  • Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain.

    abstract::RNA interference (RNAi) is an evolutionarily conserved mechanism of posttranscriptional gene-specific silencing. For in vivo applications, RNAi has been hampered until recently by inefficient delivery methods and by the transient nature of the gene suppression. Lentiviral vectors (LVs) hold great promise for gene ther...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403322611809

    authors: Van den Haute C,Eggermont K,Nuttin B,Debyser Z,Baekelandt V

    更新日期:2003-12-10 00:00:00

  • Oral gene therapy for hypoparathyroidism: a rat model.

    abstract::The use of nonionic polymeric micelles orally to protect and deliver plasmid DNA in vivo was investigated. Parathyroid hormone (PTH)(1-34) gene (179 bp) was inserted into a human cytomegalovirus promoter (PCMV) and E. coli competent cells were used to amplify the cDNA. Polymeric micelle formations (100 microl) formed ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.015

    authors: Chou FF,Huang SC,Chang SF,Liaw J,Hung PH

    更新日期:2009-11-01 00:00:00

  • New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells.

    abstract::Advances in cell and gene therapy are opening up new avenues for regenerative medicine. Because of their acquired pluripotency, human induced pluripotent stem cells (hiPSCs) are a promising source of autologous cells for regenerative medicine. They show unlimited self-renewal while retaining the ability, in principle,...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2012.251

    authors: Garate Z,Davis BR,Quintana-Bustamante O,Segovia JC

    更新日期:2013-06-01 00:00:00

  • Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8-dihydroxyadenine lithiasis.

    abstract::Deficiencies in different steps of purine metabolism give rise to a number of human inherited disorders. Lesch-Nyhan syndrome is a severe neurological disorder, caused by a deficiency in the purine salvage enzyme hypoxanthine phosphoribosyltransferase (HPRT). HPRT-deficient mice have been generated, but have proved to...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.13-1491

    authors: Redhead NJ,Selfridge J,Wu CL,Melton DW

    更新日期:1996-08-20 00:00:00

  • Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

    abstract::Abstract Our studies have shown that coinjection of conventional single-stranded adeno-associated virus 2 (ssAAV2) vectors carrying the enhanced green fluorescent protein (EGFP) gene with self-complementary (sc) AAV2-T cell protein tyrosine phosphatase (TC-PTP) and scAAV2-protein phosphatase-5 (PP5) vectors resulted i...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.100

    authors: Jayandharan GR,Zhong L,Sack BK,Rivers AE,Li M,Li B,Herzog RW,Srivastava A

    更新日期:2010-03-01 00:00:00

  • Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model.

    abstract::In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines. It results in increased DNA uptake, enhances protein expression, and augments immune responses to the target antigen in a variety of species. To further improve the efficacy of DNA-EP, we evaluated small interfering RNA (siRN...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2008.210

    authors: Dharmapuri S,Aurisicchio L,Biondo A,Welsh N,Ciliberto G,La Monica N

    更新日期:2009-06-01 00:00:00

  • Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.

    abstract::Immunotherapy with whole cell cancer vaccines has been tested in various tumor types. This study investigated the safety profile and antitumor activity of an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant human interleukin-2 and human interferon-gamma. Thirty HLA-A*0201-matched patients with pr...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.101

    authors: Brill TH,Kübler HR,Pohla H,Buchner A,Fend F,Schuster T,van Randenborgh H,Paul R,Kummer T,Plank C,Eisele B,Breul J,Hartung R,Schendel DJ,Gansbacher B

    更新日期:2009-12-01 00:00:00